The multinational pharmaceutical company, Hikma Pharmaceuticals PLC has launched a new prefilled syringe capability in the US through its affiliate, Hikma Pharmaceuticals USA Inc. Heparin Sodium Injection, USP, 5000 Units/mL is the first Hikma medicine available in prefilled syringe form. Hikma has become one of the renowned brands in US to provide most of the injectable generic medicines.
“Medical professionals are always in need of tools that help them improve the speed, safety and accuracy of patient care and that is why Hikma is excited to launch our prefilled syringe capability,” said dan Motto, Hikma’s EVP of Commercial & Business development, US Injectables. “Our Heparin Sodium Injection prefilled syringes are ready-to-administer and will help hospitals, pharmacists, doctors and nurses treat patients faster, more easily and with reduced risk. This is another example of ow Hikma is using its capabilities as a leading generic pharmaceutical company to serve the growing needs of US medical professionals and their patients,”
“Hikma is continuously expanding its broad and deep portfolio of essential injectable medicines” said Riad Mishlawi, President, Hikma Injectables. “We have made significant investments in our US manufacturing capabilities to bring this new prefilled syringe capability to market, and Heparin is the first of many important medicines we will deliver in this form.”
Some of the situations for which Heparin Sodium Injection is indicated re Prophylaxis and treatment of venous thrombosis and pulmonary embolism, atrial fibrillation with embolization, and so on.